{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:53:22Z","timestamp":1787756002076,"version":"build-2784847793"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In the wake of the 10-year anniversary since the introduction of chimeric antigen receptor-T (CAR-T) cell therapies to the market, the field of B cell lymphoma has seen remarkable advances since these therapies first arrived at the bedside in 2017. Modern data from longitudinal readouts attests to the high depth and durability of response to CAR-T therapies in many patients with B cell lymphomas; however, approximately 50% of patients continue to have relapsed\/refractory disease even after receipt of conventional CAR-T constructs. In this review, we discuss the mechanisms underlying primary and secondary refractoriness to conventional single-targeting CAR-T therapies for B cell lymphomas and explore the ongoing challenges with existing CAR constructs. We discuss the prospects for adaptable multi-antigen targeting via the use of bivalent CAR and bicistronic CAR functionalities as informed by recent advances in synthetic immunobiology. We explore contemporary efforts, mostly Phase 1 and 2 trials, involving bivalent CAR and bicistronic CAR constructs at the cutting edge of clinical translation. Finally, we propose evidence-based solutions to help improve the translational success of multi-antigen CAR-T therapy, including optimizing construct architecture, expanding the targetable antigen landscape, and improving scalability. These solutions for multi-antigen targeting in next-generation CARs may have substantial benefits in the coming years.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1900443","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:54Z","timestamp":1784699574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-antigen chimeric antigen receptor-T cell therapy for relapsed\/refractory B cell lymphomas"],"prefix":"10.3389","volume":"17","author":[{"given":"Toshali","family":"Pandey","sequence":"first","affiliation":[{"name":"Dept. of Medicine, Univ. of Arkansas College of Medicine","place":["Little Rock, AR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Samat","sequence":"additional","affiliation":[{"name":"Dept. of Medicine, Reading Hospital, Tower Health","place":["Reading, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Dept. of Medicine \u2013 Division of Hematology\/Oncology, UMass Memorial Medical Center, UMass Chan Medical School","place":["Worcester, MA, United States"]},{"name":"Center for Clinical and Translational Science, UMass Chan Medical School","place":["Worcester, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006245","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2022","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3036","article-title":"Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell Malignancies","volume":"40","author":"Yang","year":"2022","journal-title":"Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-Axi-Cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2018-99-120206","article-title":"Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy","volume":"132","author":"Oak","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205010","article-title":"Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic Malignancies","volume":"20","author":"Song","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018598","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-beta receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v130.suppl_1.810.810","article-title":"Novel CD19\/CD22 bicistronic chimeric antigen receptors outperform single or bivalent CARs in eradicating CD19+CD22+, CD19-, and CD22- pre-B leukemia","volume":"130","author":"Qin","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/pai.0b013e3181845ef4","article-title":"Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms","volume":"17","author":"Adams","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41467-025-68272-5","article-title":"AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape","volume":"17","author":"Ansari","year":"2026","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2024-208539","article-title":"Interim results from a phase 2 pivotal study (DALY II USA) of tandem CD20-CD19-directed non-cryopreserved CAR-T cells - zamtocabtagene autoleucel (zamto-cel) in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-669","article-title":"Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for relapsed\/refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study","volume":"146","author":"Borchmann","year":"2025","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-668","article-title":"Rondecabtagene autoleucel, an autologous, dual-targeting CD19\/CD20 CAR T-cell candidate manufactured from CD62L+enriched T cells, achieves durable responses in patients with large B-cell lymphoma","volume":"146","author":"Larson","year":"2025","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-501","article-title":"CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19\/CD20 CAR T-cell candidate","volume":"146","author":"Merchant","year":"2025","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2024-208394","article-title":"KITE-753: an autologous rapid manufactured anti-CD19\/CD20 CAR-T product for the treatment of B-cell Malignancies","volume":"144","author":"Murakami","year":"2024","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-265","article-title":"A phase 1 study of KITE-753 or KITE-363 in patients with relapsed\/refractory B-cell lymphoma: initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363","volume":"146","author":"Dahiya","year":"2025","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026401","article-title":"A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"145","author":"Yu","year":"2025","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(25)02881-2","article-title":"CT-1498: a global phase 1B study of JNJ-90014496, a CD19\/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy, in patients (pts) with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"25","author":"Patel","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2024-207532","article-title":"Initial results of a first-in-human, phase I study point-of-care manufacturing of trispecific CAR-T cells targeting CD19\/20\/22 in B-cell Malignancies","volume":"144","author":"Vasu","year":"2024","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"13","author":"Qu","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007515","article-title":"Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas","volume":"11","author":"Chu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19","volume":"25","author":"Ormhoj","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024104","article-title":"Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid Malignancies","volume":"144","author":"Frigault","year":"2024","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2172","article-title":"Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial Malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin's lymphoma and multiple myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1042\/bst20170178","article-title":"Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology","volume":"46","author":"Ebert","year":"2018","journal-title":"Biochem Soc Trans"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic Notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19001","article-title":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","volume":"203","author":"Gao","year":"2023","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70120","article-title":"Challenges and solutions to implementation of chimeric antigen receptor therapies in acute myeloid leukemia","volume":"116","author":"Maheswaran","year":"2026","journal-title":"Eur J Haematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","article-title":"CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro","volume":"19","author":"Alishah","year":"2021","journal-title":"J Transl Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1200\/jco.2024.42.16_suppl.7025","article-title":"A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): Updated phase 1 results from the ANTLER trial","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/btt.s291768","article-title":"Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biologics"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2026.10938","article-title":"How can we balance risk and benefit of interleukin-18 armored T cell therapies","volume":"251","author":"Vicenova","year":"2026","journal-title":"Exp Biol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0473","article-title":"Allogeneic CD19\/CD22 CAR T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"10","author":"Phely","year":"2024","journal-title":"JAMA Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jtct.2025.12.047","article-title":"Mature outcomes from the phase I trial of Orca-T and allogeneic CD19\/CD22 CAR-T cells for adults with high-risk B-ALL","volume":"32","author":"Molina","year":"2026","journal-title":"Transpl Cell Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1182\/blood-2024-211441","article-title":"P-CD19CD20-ALLO1: Potent fully allogeneic CAR-T therapy targeting CD19 and CD20 with superior efficacy over single-target products","volume":"144","author":"Jambon","year":"2024","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00753","article-title":"Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors","volume":"9","author":"Gerber","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:56Z","timestamp":1784699576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1900443"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1900443","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1900443"}}